Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CCT244747 is a CHK1 inhibitor (IC50: 7.7 nM) and also abrogates G2 checkpoint (IC50: 29 nM).
产品描述 | CCT244747 is a CHK1 inhibitor (IC50: 7.7 nM) and also abrogates G2 checkpoint (IC50: 29 nM). |
靶点活性 | Chk1:7.7 nM |
体外活性 | CCT244747 poorly inhibits CHK2 (IC50 >10 μM) and CDK1 (IC50 >10 μM). CCT244747 inhibits FLT3 (IC50: 600 nM) and also inhibits cellular CHK1 function with IC50s ranging from 29 nM to 170 nM for cellular G2 checkpoint abrogation (MIA, mitosis induction assay) in HT29, SW620, MiaPaCa-2, and Calu6 cell lines; the GI50s are between 0.33 and 3μM. CCT244747 (0.3 μM) inhibits SN38 and gemcitabine-induced CHK1 activity in HT29 and SW620 colon cancer cell lines and this correlates with the abrogation of cell cycle arrest, induction of DNA damage and apoptosis [2]. CCT244747 has potent activities against CHK1, RSK1, RSK2, AMPK, BRSK1, IRAK1, and TrkA, with >80% inhibition. CCT244747 (0.5-2.0 μM) increases the sensitivity of bladder and head and neck cancer cell lines (T24, RT112, and Cal27) to radiation [3]. CCT244747 (0.5 μM) overcomes genotoxic-induced S and G2 cell cycle arrest in human colon cancer cell lines. CCT244747 (10 μM) exhibits <25% inhibition of the other ion channels including hNav1.5, hKv4.3/hKChIP2, hCav1.2, hKv1.5, hKCNQ1/hminK, hHCN4 [1]. |
体内活性 | CCT244747 (100-300 mg/kg, p.o.) inhibits gemcitabine-induced pS296 CHK1 for up to 24 h in HT29 colon tumor xenografts[1]. CCT244747 (75 mg/kg, p.o.) in combination with gemcitabine has potent antitumor effects in HT29 colon tumor xenografts and Calu6 human lung cancer xenografts. CCT244747 (100 mg/kg p.o., qd7d) significantly reduces tumor burden in human tumor xenografts. CCT244747 (100 mg/kg, p.o.) exhibits radiosensitization activity in Cal27 xenografts [3]. CCT244747 (150 mg/kg p.o.) also shows antitumor activities with irinotecan in SW620 human colon tumor xenografts [2]. |
分子量 | 408.46 |
分子式 | C20H24N8O2 |
CAS No. | 1404095-34-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (244.82 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4482 mL | 12.2411 mL | 24.4822 mL | 61.2055 mL |
5 mM | 0.4896 mL | 2.4482 mL | 4.8964 mL | 12.2411 mL | |
10 mM | 0.2448 mL | 1.2241 mL | 2.4482 mL | 6.1206 mL | |
20 mM | 0.1224 mL | 0.6121 mL | 1.2241 mL | 3.0603 mL | |
50 mM | 0.049 mL | 0.2448 mL | 0.4896 mL | 1.2241 mL | |
100 mM | 0.0245 mL | 0.1224 mL | 0.2448 mL | 0.6121 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CCT244747 1404095-34-6 Cell Cycle/Checkpoint Chk CCT-244747 CCT 244747 Inhibitor inhibitor inhibit